Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of tuvonralimab + iparomlimab with docetaxel in advanced non-small cell lung cancer after progression on prior immunotherapy
ChiCTR2500103468Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tuvonralimab, iparomlimab and docetaxel in non-small cell lung cancer (NSCLC), sponsored by West China Hospital of Sichuan University. Primary endpoints: Progression-free survival and Overall survival. Started Aug 2025; status: recruiting.
02
Drugs
tuvonralimabiparomlimabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500103468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103468.